Table 7 Summary of TEAEs related to pazopanib (≥ 5.0%) by maximum toxicity grade (SAS)
Treatment-related TEAE | Pazopanib N = 190 | |||||
|---|---|---|---|---|---|---|
Grade 1 n (%) | Grade 2 n (%) | Grade 3 n (%) | Grade 4 n (%) | Grade 5 n (%) | Overall n (%) | |
Number of patients with at least one TEAE | 103 (54.2) | 87 (45.8) | 41 (21.6) | 0 | 3 (1.6) | 138 (72.6) |
Hypothyroidism | 3 (1.6) | 8 (4.2) | 0 | 0 | 0 | 11 (5.8) |
Diarrhoea | 39 (20.5) | 12 (6.3) | 7 (3.7) | 0 | 0 | 58 (30.5) |
Nausea | 15 (7.9) | 3 (1.6) | 1 (0.5) | 0 | 0 | 19 (10.0) |
Vomiting | 10 (5.3) | 5 (2.6) | 1 (0.5) | 0 | 0 | 16 (8.4) |
Stomatitis | 9 (4.7) | 2 (1.1) | 1 (0.5) | 0 | 0 | 12 (6.3) |
Fatigue | 5 (2.6) | 10 (5.3) | 1 (0.5) | 0 | 0 | 16 (8.4) |
Alanine aminotransferase increased | 5 (2.6) | 2 (1.1) | 4 (2.1) | 0 | 0 | 11 (5.8) |
Aspartate aminotransferase increased | 4 (2.1) | 5 (2.6) | 1 (0.5) | 0 | 0 | 10 (5.3) |
Transaminases increased | 4 (2.1) | 2 (1.1) | 4 (2.1) | 0 | 0 | 10 (5.3) |
Decreased appetite | 11 (5.8) | 7 (3.7) | 0 | 0 | 0 | 18 (9.5) |
Palmar-plantar erythrodysesthesia syndrome | 21 (11.1) | 5 (2.6) | 2 (1.1) | 0 | 0 | 28 (14.7) |
Hair colour changes | 16 (8.4) | 0 | 0 | 0 | 0 | 16 (8.4) |
Rash | 8 (4.2) | 2 (1.1) | 0 | 0 | 0 | 10 (5.3) |
Hypertension | 3 (1.6) | 17 (8.9) | 7 (3.7) | 0 | 0 | 27 (14.2) |